Zaoqu Liu1,2,3†
Yuqing Ren4†
Lingfang Meng5†
Lifeng Li6
Richard Beatson7
Jinhai Deng8Tengfei Zhang9*Junqi Liu10*
Xinwei Han1,2,3*- 1Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 2Interventional Institute of Zhengzhou University, Zhengzhou, China
- 3Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China
- 4Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 5Department of Ultrasound, Zhengzhou Sixth People’s Hospital, Henan Infectious Disease Hospital, Zhengzhou, China
- 6Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China
- 7School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
- 8Richard Dimbleby Laboratory of Cancer Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
- 9Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 10Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Malignant tumors pose a great challenge to human health, which has led to many studies increasingly elucidating the tumorigenic process. Cancer Stem Cells (CSCs) have profound impacts on tumorigenesis and development of drug resistance. Recently, there has been increased interest in the relationship between inflammation and CSCs but the mechanism underlying this relationship has not been fully elucidated. Inflammatory cytokines produced during chronic inflammation activate signaling pathways that regulate the generation of CSCs through epigenetic mechanisms. In this review, we focus on the effects of inflammation on cancer stem cells, particularly the role of signaling pathways such as NF-κB pathway, STAT3 pathway and Smad pathway involved in regulating epigenetic changes. We hope to provide a novel perspective for improving strategies for tumor treatment.
Introduction
Cancer remains one of the most devastating diseases in the world. For decades, the occurrence and progression of tumors has been attributed to abnormal genetic changes such as mutations and chromosomal instabilities. However, recent advances in genome sequencing technologies and epigenetic analysis have led to the discovery that epigenetics play critical roles in the regulation of biological characteristics of cells and their malignant transformation (Dawson and Kouzarides, 2012). Furthermore, the identification of cancer stem cells (CSCs) and their association with chemoresistance and tumor relapse has also been a key discovery in the study of cancer (Visvader, 2011). Epigenetic mechanisms have been shown to play a significant role in the development of CSCs. On the other hand, inflammation has also been associated with tumorigenesis. Inflammation is a beneficial response of the immune system to tissue damage and pathogens. However, prolonged immune response leads to chronic inflammation that can promote malignant transformation of cells (Elinav et al., 2013). Several studies have demonstrated that chronic inflammation is involved in tumor development and progression. This has led to the emergence of a new field of cancer research involving the regulation of CSCs by chronic inflammation. Chronic inflammation can regulate the proliferation, metabolism, and differentiation of tumor cells as well as the self-renewal ability of CSCs by inducing secretion of inflammatory factors, oxidative stress and hypoxia. Therefore, it is crucial to understand the interaction between inflammatory factors and CSCs. Recently, epigenetic mechanisms have been shown to regulate inflammation and the generation of CSCs in cancer, and several molecular mechanisms underlying these processes have been elucidated. Importantly, epigenetic mechanisms have been associated with the variability observed in therapeutic responses. Therefore, an in-depth analysis of the relationship among CSCs, epigenetics and inflammation is not only critical in the understanding of tumor characteristics, but it is also key in the development of therapeutic strategies against tumors. In this review, we focus on the characteristics of CSCs, epigenetic clues, and the effects of epigenetic signaling pathways, particularly the effects of inflammation related factors on tumorigenesis, progression, and therapeutic response. We also discuss recent advances in targeting CSCs using epigenetic therapies.
Cancer Stem Cells
Cancer stem cells are small subsets of cells with capacity for self-renewal and the ability to differentiate into the different cell types that constitute a tumor (Reya et al., 2001). Therefore, these cells have the same stem cell-like properties as normal tissue stem cells. CSCs also exhibit capacity for spheroid formation, migration, invasion, and development of drug resistance, thus contributing to tumor cell proliferation. It should be noted that a general differentiation capacity is not an obligatory feature of CSCs. The ability of CSCs to differentiate and repopulate cell types found in the original tumor is of greater significance.
In 1937, Furth and Kahn successfully engrafted single mouse leukemia cells that developed into leukemia (Furth et al., 1937), demonstrating for the first time the existence of cancer cells with stem cell-like properties. These cancer cells are now termed cancer stem cells or tumor-initiating cells. In the early 1990s, human leukemic stem cells were identified and transplanted by Dr. John Dick (Furth et al., 1937; Lapidot et al., 1994). Similarly, recent studies have shown that CSCs also play a critical role in the development of several solid tumors, including prostate, brain, colon, pancreatic, and breast cancers (Chen et al., 2012; Meacham and Morrison, 2013). This has led to the emergence of a field of research in cancer stem cells which has increased the understanding of cancer and renewed the hope of cancer eradication. CSCs arise due to mutations in normal stem cells, cancer cells that have undergone epithelial-mesenchymal transition (EMT), or dedifferentiated somatic cells. However, the molecular mechanisms underlying the development of CSCs have not yet been well elucidated. Recent reports have revealed the role of microRNAs (miRNAs) in regulating CSCs (Liu et al., 2011; Asadzadeh et al., 2019; Khan et al., 2019). In addition, several cell surface markers, including CD24, CD44, CD133 and aldehyde dehydrogenase 1 (ALDH1), have been identified, classified and used to isolate CSCs (Yu et al., 2012). Evidence shows that these markers, especially those on the surface of CSCs, are cancer specific (Hao et al., 2014). Moreover, cancer stem cells are one of the major causes of tumor heterogeneity and acquired drug resistance.
Overall, CSCs have the potential for self-renewal and heterogeneous differentiation, leading to tumor formation (Krishnamurthy and Nor, 2012). CSCs can also arise when epigenetic reprogramming induces dedifferentiation of normal cells resulting in the cells acquiring stem cell-like properties. A major difference between normal stem cells and cancer stem cells is their ability to modulate stemness pathways. In normal stem cells, stemness pathways including TGF-β, Wnt/β-Catenin, notch, and Janus kinase/signal transducer and activator of transcription, among others, are tightly controlled by complete genetics or epigenetics. In contrast, the regulation of these pathways in CSCs is not tightly controlled, and their deregulation as well as inappropriate interactions among the pathways may contribute to the propagation and pathogenicity of CSCs. In addition, cells in the tumor microenvironment, such as cancer-associated fibroblasts, can trigger growth and differentiation of CSCs by secreting growth factors or activating signaling pathways through cell-cell interactions (Lopez-Lazaro, 2015; Batlle and Clevers, 2017; Asadzadeh et al., 2019).
Inflammatory Microenvironment and Cancer Stem Cells
Inflammation is a self-limiting physiological response that mediates the repair of damaged tissues. However, chronic inflammation has been associated with several human diseases, including cancer (Hu et al., 2017). The microenvironment of normal stem cells as well as cancer stem cells is critical for their maintenance and function. Inflammatory factors present in the tumor microenvironment control tumor initiation, progression, and the nature of CSCs (Plaks et al., 2015; Figure 1). Inflammation promotes the acquisition and maintenance of the cancer stem cell phenotype by stimulating EMT (Rhim et al., 2012). The secretion of inflammatory cytokines creates an inflammatory microenvironment which also leads to the generation of CSCs (Scheel and Weinberg, 2012; Nieto, 2013; Nieto et al., 2016). Current studies show that the maintenance of the cancer stem cell phenotype and function is more complex than previously thought. Therefore, it is important to elucidate the signaling pathways that regulate cancer stem cell phenotype and function. During their growth, tumors recruit various types of immune cells into the tumor microenvironment. These immune cells change their phenotype and function within the tumor cells to promote tumor growth and metastasis. Additionally, these infiltrating immune cells cause inflammation in the tumor tissue by inducing the secretion of growth factors, cytokines, chemokines, proteases, and extracellular matrix modifying enzymes (Bierie and Moses, 2010). For instance, transforming growth factor-β induces the EMT phenotype in breast cancer which confers stem cell-like properties to normal and transformed mammary epithelial cells (Hollier et al., 2009). These inflammatory cells, together with the active factors they secrete, shape the microenvironment on which CSCs depend on for their generation and their ability to stimulate and protect cancer stem cells to maintain their self-renewal ability.
Figure 1. The molecular and cellular basis of interaction between cancer stem cells (CSCs) and tumor microenvironment. The CSCs interact with mesenchymal stem cells (MSCs), tumor-associated macrophages (TAMs), fibroblasts, and cancer cells, which produce a large number of growth factors and cytokines, such as IL-6, IL-8, TGF-β, and TNF-α. Those factors play an important role in inducing self-renewal, plasticity, dormancy, metastasis, and tumorigenesis of CSCs.
Tumor-associated macrophages (TAMs) play a crucial role in the development of cancer (Biswas et al., 2013). TAMs are the main types of infiltrating immune cells in breast cancer as well as malignant glioma tissues, accounting for approximately 5 to 50% of all cells in the tumor tissues. These TAMs secrete a number of factors, including interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), which have been shown to promote tumor invasion and metastasis (Biswas et al., 2013). TAMs also secrete other cytokines such as IL-6, IL-8, and CSF2, which maintain the stemness of tumors through paracrine mechanisms (Lu et al., 2014). In addition to various factors secreted by immune cells and stromal cells in the tumor microenvironment to regulate cancer stem cells, cytokines secreted by tumor cells can also act on cancer stem cells in an autocrine manner. Recently, Iliopoulos et al. (2011) reported that the pro-inflammatory cytokine, IL-6, can transform non-cancer stem cells into cancer stem cells. Colorectal cancer cells exposed to IL-6 suppressed EMT transcription factor expression, as well as the invasion, and metastasis of the cancer cells by repressing IL-6 through expression of miR-34a (Rokavec et al., 2014). In transformed breast cells, IL-6 reduces the expression levels of let-7 by activating Lin28 transcription via the NF-κB pathway, leading to the development of breast cancer and enhanced CSC characteristics (Iliopoulos et al., 2009; Shyh-Chang and Daley, 2013). IL-6 also promotes the expression of miR-203 in stem cells by downregulating the EMT activator ZEB1 thus linking EMT activation to stemness maintenance (Wellner et al., 2009). In addition, HER2 + breast cancer cells that develop resistance to trastuzumab treatment are enriched with CSCs, exhibit EMT features and express high levels of IL-6. Blockade of the IL-6 receptor reduced the tumor proliferative capacity of these cells, further indicating that IL-6 regulates CSCs through an autocrine loop (Korkaya et al., 2012). Long et al. (2012) reported that ovarian cancer stem cells promote tumor metastasis by expressing high levels of CCL5, activating the NF-κB signaling pathway in an autocrine manner and up-regulating the expression of MMP-9. Ginestier et al. (2010) reported that breast cancer stem cells highly expressed CXCR1 receptor, and that IL-8 (a ligand of CXCR1) was able to enhance the proportion of CSCs and maintain the stemness of CSCs. The communication between tumor cells and the tumor environment is bidirectional. The factors secreted by cancer stem cells attract necessary cells to their environment, and these cells secrete factors that are beneficial to cancer stem cells, thereby coexisting harmoniously.
Effects of Inflammatory Factors on Epigenetic of Cancer Stem Cells
Epigenetic regulation of the genome is one of the main mechanisms of altering the genetic code to control the hierarchy of cell development. Epigenetic mechanisms refer to changes in gene expression that are not caused by changes in DNA sequence but by changes in DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA, such as microRNAs (miRNAs). These epigenetic mechanisms control the genetic landscape and dictate cell fate (Hu et al., 2017). Such changes in the genome are very important during normal mammalian development and differentiation of ESCs (Reik, 2007), and any alteration in epigenetic signaling can affect the accumulation of cells with stemness and self-renewing capacity, to produce CSCs. DNA hypermethylation of cytosines in CpG dinucleotides in various cancers has been associated with silencing of tumor suppressors and genes regulating differentiation (Esteller, 2007). A decrease in the expression of these two types of genes may contribute to the development of CSCs in the tumor cell populations (Jones and Baylin, 2007; Ohm et al., 2007). DNA methylation silences transcription by recruiting methyl-CpG binding domain proteins that are able to induce histone modifying enzymes to promote repressive histone modifications (Wade et al., 1999; Baylin et al., 2011; Easwaran et al., 2014), or to a lesser extent, facilitate expression by preventing access to transcription factors (Bell and Felsenfeld, 2000; Hark et al., 2000). DNA methylation is regulated by three DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) (Bird, 2002). Actually, it has been reported that DNA methylation plays an important role in maintaining the characteristics of CSCs in leukemia, lung, and colon stem cells (Broske et al., 2009; Morita et al., 2013; Liu C.C. et al., 2015). Moreover, inflammation can promote tumorigenesis by inducing epigenetic alterations in cells. In most cases, epigenetic inheritance cannot be explained by a single alteration, but by the interaction of different epigenetic mechanisms. Many inflammatory factors regulate the DNA methylation patterns that induce cancer initiation and progression in cancers such as gastric cancer, ovarian cancer, and liver cancer. IL-1β is a proinflammatory cytokine that enhances the activity of DNMT through the production of nitric oxide in gastric cancer, leading to CpG methylation-mediated gene silencing (Hmadcha et al., 1999). Additionally, TGF-β can induce the expression and activity of DNMTs, leading to integral changes in DNA methylation during the EMT of ovarian cancer (Cardenas et al., 2014) and the acquisition of stemness by cancer cells. In breast cancer, TGF-β induces endothelial cell transformation by recruiting DNMT and histone methyltransferases (EHMT2 and SUV39H1) to the CDH1 gene promoter, which leads to the development of CSCs (Dong et al., 2012, 2013; David and Massague, 2018). Epigenetic processes also control the IL-6-mediated induction of cancer cell stemness (Drost and Agami, 2009; Iliopoulos et al., 2009, 2010a). It has been shown that p53 recruits DNMT1 to the promoter of its target genes (Esteve et al., 2005). The deletion of p53 leads to the demethylation of the IL-6 promoter thus activating IL-6 signaling. Subsequently, IL-6 signaling upregulates DNMT1 which methylates the promoter of the p53 gene (Hodge et al., 2005, 2007; Liu C.C. et al., 2015), thus initiating an IL-6 autocrine loop (D’Anello et al., 2010). Therefore, the activation of this IL-6 autocrine loop drives cancer cells toward a stem-like phenotype through epigenetic reprogramming (D’Anello et al., 2010; Liu C.C. et al., 2015). IL-6 also facilitates hypermethylation of the promoter of the miR142-3p gene, thereby inhibiting the expression of miR-142-3p. These effects promote cell stemness and invasiveness in glioblastoma (Chiou et al., 2013). Thus, cytokine signaling promotes CSCs through epigenetic mechanisms. More importantly, inflammatory cytokines such as TGF-β, TNF-α, IL-1, and IL-6 activate signal transduction pathways such as Smads, NF-κB and STAT3 pathways by recruiting epigenetic regulators. These inflammatory pathways are interconnected and produce molecular regulatory circuits and networks to control the generation and maintenance of CSCs.
Nuclear Factor-κB Pathway
Nuclear factor-κB (NF-κB) is an inducible transcription factor that regulates the transcription of its target genes (Zhang et al., 2017), and plays key roles in inflammatory responses and cancer development (Hoesel and Schmid, 2013). The NF-κB family of transcription factors regulate inflammation, self-renewal or maintenance and metastasis of immune cells and CSCs. Furthermore, the NF-κB pathway is also involved in cell survival, proliferation, and differentiation (Hayden and Ghosh, 2008), and is considered to play key roles in the many steps involved in cancer initiation and progression. Moreover, cytokines, growth factors, angiogenic factors, and proteases produced during tumor development and progression can activate the NF-κB signaling pathway (Figure 2). The NF-κB family consists of five members: NF-κB1, NF-κB2, c-Rel, RelB, and p65. The members of this family have a conserved N-terminal Rel homologous domain that is involved in nuclear localization, DNA binding, homodimerization, and heterodimerization. The p50-p65 dimer is the primary functional form of NF-κB (May and Ghosh, 1997; Hayden and Ghosh, 2008; Hoesel and Schmid, 2013), which is mainly regulated through subcellular localization. The activation of the NF-κB pathway involves the translocation of the transcription factor complex from the cytoplasm to the nucleus (Novack, 2011). The activity of the transcription factor multiplex is regulated through either canonical NF-κB signaling or the non-canonical NF-κB signaling. The canonical NF-κB signaling pathway is activated by ligands (such as bacterial components, IL-1β, TNF-α, and lipopolysaccharide) binding to their respective receptors (such as toll-like receptors, IL-1 receptors, TNF receptors, and antigen receptors) (Perkins and Gilmore, 2006). Activation of these receptors leads to the phosphorylation and activation of IκB kinase (IKK), which subsequently initiates phosphorylation of IκB proteins. The receptors involved in the activation of the non-canonical pathway include receptor activator for NF-κB, B cell activating factor, CD40, and lymphotoxin β receptors (Sun, 2011). This pathway activates NF-κB through the inducible kinase (NIK), which predominantly phosphorylates and activates IKK1. IKK1 then induces the phosphorylation of p100 to generate p52 (Xiao et al., 2001).
Figure 2. The progress of two main NF-κB signaling pathways. In a canonical way, the main physiological function of NF-κB is the p50–p65 dimer. The active p50–p65 dimer is further facilitated by post-translational modification and accumulates in the nucleus to regulate the expression of target genes in combination with other transcription factors. In non-canonical way, IKKα homodimers transform RelB–p100 dimer into RelB–p52 dimer driven by signaling factors, which activate non-canonical NF-κB target genes to express consequently.
In esophageal cancer, the up-regulation of PLCE1 oncoprotein through epigenetic mechanisms drives esophageal cancer angiogenesis and proliferation by activating the NF-κB signaling pathway. Hypomethylation-induced PLCE1 in esophageal squamous cell carcinoma (ESCC) cohorts can bind and phosphorylate p65 and IκBα proteins. Subsequently, phosphorylated IκBα promotes nuclear translocation of p50/p65 and p65, where they act as transcription factors for vascular endothelial growth factor-C and bcl-2, driving tumor angiogenesis and inhibits apoptosis in vitro (Chen et al., 2019). Likewise, Sox9 is demethylated in pancreatic cancer stem cells and is involved in the invasion process. Several studies have identified a potential NF-κB binding site on the Sox9 promoter, and demonstrated that the p65 subunit of NF-κB positively regulates Sox9 expression by directly binding to its promoter (Sun et al., 2013). Inhibition of DNA of methyltransferase activity causes demethylation of the Sox9 promoter, which leads to the enrichment of p65 on the Sox9 promoter and up-regulation of Sox9 expression. These results indicate that regulation of Sox9 by NF-κB is dependent on its methylation status, and demethylation may enhance NF-κB binding to the Sox9 promoter (Sun et al., 2013). In skin cancer, Ras/NF-κB-induced epigenetic silencing of Let-7c, an upstream regulator of NF-κB, causes HaCaT cells to acquire cancer stem cell-like properties and undergo neoplastic transformation (Jiang R. et al., 2014). In addition, MiRNAs have recently been reported to regulate the NF-κB signaling pathway. For instance, MiR-210-3p maintains sustained activation of NF-κB signaling by targeting TNIP1 and SOCS1, negative regulators of NF-κB signaling, leading to EMT, invasion, migration, and bone metastasis of prostate cancer cell (Ren et al., 2017b). MiR-372/373 enhances the stemness features of colorectal cancer by acting on various signaling mechanisms associated with stem cell differentiation. It can inhibit the NF-κB, MAPK/Erk, and VDR signaling pathways that are essential for differentiation (Khan et al., 2019). Downregulation of miR-136 stimulates CSCs by activating various proteins including NF-κB, survivin, BCL2, CyclinD1, and BCL2. On the other hand, upregulation of miR-155 activates NF-κB (Khan et al., 2019).
STAT3 Pathway
The JAK/STAT3 signaling pathway plays crucial roles in various types of cancer. Activation of this pathway enhances EMT leading to increased tumorigenic and metastatic capacity, development, transition of CSCs, and chemoresistance of cancer. The STAT family has seven members (STAT1, 2, 3, 4, 5α, 5β, and 6). Each STAT protein has highly conserved amino terminal, SH2, coiled-coil, DNA binding, and transactivation domains (Darnell, 1997). The SH2 domain is indispensable for the interaction between STAT proteins and STAT cytokine receptors. This is because the cytokine receptors recognize and bind to tyrosine residues on the SH2 domain. The SH2 domain is also essential in the formation of stable homodimers or heterodimers with other STAT proteins (Heim et al., 1995; Hemmann et al., 1996). Cytokines induce dimerization of STAT3 via acetylation of Lys685 in the SH2 domain of STAT3, which is mediated by histone acetyltransferase p300 (Yuan et al., 2005). Other transcription factors interact with the Asp170 residue in the coiled-coil domain of STAT3 (Zhang et al., 1999), and their receptor binding, DNA binding, nuclear translocation and dimerization all require IL-6-induced tyrosine phosphorylation of STAT3 (Zhang et al., 2000). In addition, the N-terminal domain of STAT3 has various functions including stabilization of STAT3 tetramers, nuclear translocation, cooperative DNA binding, and protein-protein interactions (Hu et al., 2015).
STAT3 also induces the transcription of genes involved in the inflammatory response. Sakamoto et al. (2016) found that Janus kinase 1 (Jak1) played a significant part in inflammatory cytokine signaling and remodeling of the mammary gland. STATs are also involved in the regulation of apoptosis, differentiation, and stem cell maintenance. STAT3 and STAT5 have been shown to play different roles in breast cancer. Walker et al. (2014) reported that STAT5 regulates STAT3 and they both play a role in breast cancer progression. Intestinal inflammation also promotes tumorigenesis by enhancing tumor cell survival and proliferation. Members of the IL6, IL10/IL22, and IL17/IL23 cytokine families have been implicated in this process. They all bind to their receptors, leading to persistent, non-transient activation of STAT3, which not only promotes the growth of malignant cells but also inhibits the anti-tumor effects of both innate and acquired immune cells. This allows inflammation-associated and sporadic gastrointestinal tumors to grow (Ernst et al., 2014). STAT3 also controls the fate of prostate cancer cells, the interaction of tumor cells with the microenvironment, and maintains the number of CSCs (Kroon et al., 2013). JAK2/STAT3 signaling also plays an important role in promoting colorectal stem cell persistence and radio-resistance by inhibiting apoptosis and enhancing clonogenic potential (Park et al., 2019). Upregulation of IL-6 in colorectal cancer-derived mesenchymal stem cells (CC-MSCs) leads to enhanced metastasis and survival of colorectal cancer patients by activating PI3K/Akt via the IL-6/JAK2/STAT3 signaling pathway (Ma et al., 2019).
STATs not only act as transcriptional inducers, but they also induce epithelial mesenchymal transition and generate an oncogenic microenvironment (Li et al., 2011). Dr. Lee reported that non-canonical signaling by histone-lysine N-methyltransferase EZH2 in regulating STAT3 methylation is required for glioblastoma stem cell maintenance (Kim et al., 2013). IL-6 through STAT mediated induction of cancer cell stemness is also controlled by epigenetic processes (Drost and Agami, 2009; Iliopoulos et al., 2009, 2010a,2010b; Zahnow and Baylin, 2010; Rokavec et al., 2016). The tumor suppressor gene p53 recruits the DNMT1 methylase to the promoters of its target genes (Esteve et al., 2005). The loss of p53 expression is associated with the demethylation of the IL-6 promoter, which initiates an IL-6 autocrine loop (D’Anello et al., 2010). IL-6 signaling upregulates DNMT1 which in turn methylates the promoter of the p53 gene (Hodge et al., 2005, 2007; Liu C.C. et al., 2015). It also leads to the activation and acetylation at Lys685 of STAT3 in tumor cells, which is critical for the inactivation of tumor suppressor genes through the methylation of their promoters (Lee et al., 2012). Thus, the generation of this autocrine IL-6 loop induces epigenetic reprogramming that drives cancer cells to acquire a stem cell-like phenotype (D’Anello et al., 2010; Liu C.C. et al., 2015). Additionally, miRNAs can stimulate or inhibit the function of CSCs. IL-6/STAT3 mediated miR-200c transformation and inhibited EMT process in breast (Rokavec et al., 2012) and lung (Zhao et al., 2013) epithelial cancer cells. More importantly, the up regulation of miR-196b-5p and miR-500a-3p as well as the down-regulation of miR-218 activates STAT3 molecule. MiR-196b-5p plays a central role in maintaining CSCs characteristics associated with resistance to cancer therapy by targeting STAT3 signaling pathway in colorectal cancer stem cells (Ren et al., 2017a). Downregulation of miR-218 in lung cancer cells can induce constitutive activation of STAT3, which is closely associated with tumorigenesis. In ALDH positive lung CSCs, aberrant expression of miR-218 upregulated IL-6/JAK-STAT3 signaling and stemness features of tumors (Yang et al., 2017). Similarly, miRNAs have been associated with aberrant activation of the STAT pathway in breast and colorectal cancers (Ren et al., 2017a; Vahidian et al., 2019).
Smad Pathway
Smad transcription factor mediates signal transduction by the TGF-β cytokine superfamily to control a variety of cell responses, including development, stem cell maturation and carcinogenesis (Massague, 2012). It also plays a variety of roles in embryonic development, adult tissue regeneration and homeostasis, such as cell proliferation, differentiation, apoptosis and dynamic balance. There are at least nine Smad proteins that are divided into three subfamilies based on their structure and function: receptor activated or pathway restricted Smads (R-Smads), common Smads (Co-Smads), and inhibitory Smads (I-Smads) (Moustakas et al., 2001; Brown et al., 2017). Smad proteins regulate the transcription of their target genes by binding to specific DNA sequences in the promoter regions and recruiting either co-activators or co-repressors (Massague et al., 2005). Smad3 is the major effector of TGF-β-mediated endothelial cell transformation or differentiation. Ligand binding to the TGF-β receptor complex on the cell surface induces phosphorylation of the C-terminal of type I receptor and activates Smad2 and Smad3. These two the then form an isomer complex with Smad4, translocate into the nucleus, and interact with bound transcription factors to activate or inhibit TGF-β/Smad target genes (Singh et al., 2019). Co-Smads such as Smad4 mediate TGF-β signal transduction processes, while I-Smads, such as Smad6 and Smad7, regulate signaling by the TGF-β family by binding to activated type I receptors (Massague et al., 2005).
TGF-β1/Smad pathway is closely associated with tissue fibrosis (Xu et al., 2016; Hu et al., 2018; Ma and Meng, 2019). Several studies have reported that TGF/Smad signaling is activated in human cancers. The pathway also plays an important role in the proliferation of CSCs. In breast cancer and cutaneous squamous cell carcinoma, TGF-β has been shown to initiate tumor formation and promote the generation of CSCs (Pang et al., 2018; Najafi et al., 2019; Singh et al., 2019). Moreover, recent studies have reported that TGF-β1 is associated with the malignant behavior of tumors (Pang et al., 2018; Najafi et al., 2019). For example, high expression of TGF-β1 regulates EMT-related genes through Smad signaling, thereby promoting the progression of colorectal cancer. Recent research studies have suggested that epigenetic mechanisms play a critical role in the TGF-β1/Smad pathway. Tang et al. (2015) found that profilin-2 (Pfn2) enhances Smad2 and Smad3 expression through epigenetic mechanisms in lung cancer. Profilin-2 inhibits the recruitment of histone deacetylase (HDAC) to the Smad2 and Smad3 promoters by preventing the nuclear translocation of HDAC1 at the C-terminus of these proteins. This leads to the transcriptional activation of Smad2 and Smad3, which increases their expression levels and promotes lung cancer growth and metastasis (Tang et al., 2015). TGF-β induces epigenetic regulation of the hepatoma stem cell marker CD133 through the Smad pathway. TGF-β1 also regulates the expression of CD133 by inhibiting the expression of DNMT1 and DNMT3b, which in turn leads to the demethylation of the CD133 promoter. HCC cells containing CD133 with demethylated promoters are characterized by chemoresistance, self-renewal, and multilineage differentiation (You et al., 2010). Similarly, HDAC dependent epigenetic modifications regulate the TGF-β/Smad pathway in glioblastoma (GBM), which plays an important role in GBM tumorigenesis, resistance to common therapies and poor clinical outcomes (Sferra et al., 2017). In addition to alterations in DNA and histones, miRNAs have also been found to act as epigenetic modulators of the TGF-β/Smad signaling pathway. In CD44 (+) GCSCs, miR-106b regulates TGF-β/Smad signaling to enhance stemness characteristics of GCSCs, including EMT, self-renewal and invasion (Yu et al., 2014). MiR-4666-3p and miR-329 inhibit the stemness of colorectal cancer cells by targeting TGF-β/Smad pathway (Ye et al., 2019). MiR-148a can repress TGF-β/Smad2 signaling pathway in liver cancer stem cells (Jiang F. et al., 2014). Moreover, Smad7 is a newly identified target gene of miR-106b, which acts as an inhibitor of TGF-β/Smad signaling pathway, and suppresses gastric cancer stem cell spheroid formation (Yu et al., 2014).
Cancer Stem Cells Targeting Therapeutic Using Epigenetic Modifying Drugs
The ability of CSCs to resist therapy is widespread and in the main cause of multidrug resistance in tumors. This ability stems from the increased expression of detoxifying enzymes, and improved activation of survival signaling pathways, DNA repair mechanisms, and drug efflux pumps in CSCs (Dawood et al., 2014; Dzobo et al., 2016). Recently, CSCs have also been shown to undergo epigenetic reprogramming, which makes it difficult to eradicate them in cancer (Dymock, 2016). The involvement of epigenetic mechanisms in CSC formation and maintenance makes epigenetics a potential therapeutic target for CSCs. Therefore, small molecule compound inhibitors with the ability of inducing the differentiation of CSCs are the most promising agents against such tumor cells. Many inhibitors of epigenetic regulatory enzymes such as histone deacetylases (HDACs), histone acetyltransferases (HATS) and DNA methyltransferases (DNMTs), have been extensively studied and are currently in clinical trials for the treatment of several cancers. Furthermore, deregulation of chromatin remodeling has been implicated in tumor initiation and progression, which makes chromatin remodeling proteins effective targets for small molecule inhibitors. Indeed, a large number of these therapeutic strategies intend to induce the differentiation of CSCs and to improve the sensitivity of these cells to chemotherapy, with the ultimate goal of decreasing tumor recurrence and increasing patient survival. Inhibitors of DNA methylation were the first epigenetic drugs tested for cancer treatment (Sharma et al., 2010). The most widely studied DNMT inhibitors include azacitidine and decitabine, which are analogs of cytosine. These molecules are incorporated into DNA and covalently bind to DNA methyltransferases thus inhibiting their functions (Juttermann et al., 1994; Stresemann and Lyko, 2008), and leading to their degradation (Ghoshal et al., 2005). Liu C.C. et al. (2015) showed that inhibition of DNMT1 reduced the proliferation and tumorigenic capacity of lung cancer stem cells. The acetylation of histone tails is mediated by HATS and HDACs. Voinostat and romidessin are HDAC inhibitors that have been approved for the treatment of cutaneous T-cell lymphoma (Olsen et al., 2007; Piekarz et al., 2009). Travaglini et al. (2009) found that the HDAC inhibitor, valproic acid, was able to epigenetically reprogram breast cancer cells to a more “physiological” phenotype, thereby increasing sensitivity to other forms of breast cancer therapy. In the same way, there has recently been increased interest in the research on the epigenetic regulation of CSCs by histone lysine methyltransferase (HKMT) inhibitors and histone demethylase (HDM) inhibitors (Schenk et al., 2012; Liu K. et al., 2015; McGrath and Trojer, 2015). Further, since signaling pathways play crucial roles in promoting the propagation of CSCs, maintaining the CSC phenotype, and embryonic development (Matsui, 2016; Krishnamurthy and Kurzrock, 2018; Pan et al., 2018), therapeutic targets against these pathways have been developed. These signaling pathways include NF-κB, JAK-STAT and TGF/Smad. Specifically, targeting epigenetic changes in signaling pathways has emerged as a new research direction in tumor therapy. For example, tocilizumab inhibits IL-6/STAT3 signaling and suppresses cancer/inflammation epigenetic IL-6/STAT3/NF-κB positive feedback loop, which has tremendous therapeutic value for patients with refractory triple negative breast cancer (TNBC) (Alraouji et al., 2020). Additionally in pancreatic cancer stem cells, activation of the NF-κB pathway relies on methylation of the downstream regulatory gene Sox9, and DNMT inhibitors could perhaps be a new therapeutic strategy for pancreatic cancer treatment (Sun et al., 2013).
Conclusion
Epigenetic mechanisms play a significant role in the development of cancer stem cells. Likewise, chronic inflammation is closely associated with the initiation and progression of CSCs. These interactive processes influence and promote each other, thereby modulating the self-renewal capacity, drug-resistant properties, and metastatic potential of CSCs. We have discussed several crucial aspects and examples of signaling pathways associated with inflammation and epigenetics which drive or promote tumorigenesis and metastasis, particularly in CSCs. Some therapeutic directions and drugs targeting epigenetic mechanisms are also exemplified in this article. The regulation of epigenetic mechanisms by inflammation plays a key role in CSCs generation. Therefore, a systematic understanding of the signaling pathways associated with epigenetic regulatory mechanisms in the tumor inflammatory microenvironment can give more insights into the process of tumorigenesis. This will help identify novel strategies for tumor therapy.
Author Contributions
ZL designed the work. YR collected the materials and wrote the manuscript. ZL, XH, TZ, RB, JL, LM, JD, and LL edited and revised the manuscript. All authors have read and agreed to the published version of the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Alraouji, N. N., Al-Mohanna, F. H., Ghebeh, H., Arafah, M., Almeer, R., Al-Tweigeri, T., et al. (2020). Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol. Carcinog. 59, 1041–1051. doi: 10.1002/mc.23234
Asadzadeh, Z., Mansoori, B., Mohammadi, A., Aghajani, M., Haji-Asgarzadeh, K., Safarzadeh, E., et al. (2019). microRNAs in cancer stem cells: biology, pathways, and therapeutic opportunities. J. Cell Physiol. 234, 10002–10017. doi: 10.1002/jcp.27885
Batlle, E., and Clevers, H. (2017). Cancer stem cells revisited. Nat. Med. 23, 1124–1134. doi: 10.1038/nm.4409
Baylin, S. B., Jones, P. A., and decade, A. (2011). of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726–734. doi: 10.1038/nrc3130
Bell, A. C., and Felsenfeld, G. (2000). Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405, 482–485. doi: 10.1038/35013100
Bierie, B., and Moses, H. L. (2010). Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 21, 49–59. doi: 10.1016/j.cytogfr.2009.11.008
Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21. doi: 10.1101/gad.947102
Biswas, S. K., Allavena, P., and Mantovani, A. (2013). Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35, 585–600. doi: 10.1007/s00281-013-0367-7
Broske, A. M., Vockentanz, L., Kharazi, S., Huska, M. R., Mancini, E., Scheller, M., et al. (2009). DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 41, 1207–1215. doi: 10.1038/ng.463
Brown, J. A., Yonekubo, Y., Hanson, N., Sastre-Perona, A., Basin, A., Rytlewski, J. A., et al. (2017). TGF-beta-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. Cell Stem Cell 21, 650–664.e8. doi: 10.1016/j.stem.2017.10.001
Cardenas, H., Vieth, E., Lee, J., Segar, M., Liu, Y., Nephew, K. P., et al. (2014). TGF-beta induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics 9, 1461–1472. doi: 10.4161/15592294.2014.971608
Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., et al. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526. doi: 10.1038/nature11287
Chen, Y., Wang, D., Peng, H., Chen, X., Han, X., Yu, J., et al. (2019). Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCepsilon-NF-kappaB signaling pathway and VEGF-C/Bcl-2 expression. Mol. Cancer 18:1. doi: 10.1186/s12943-018-0930-x
Chiou, G. Y., Chien, C. S., Wang, M. L., Chen, M. T., Yang, Y. P., Yu, Y. L., et al. (2013). Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol. Cell 52, 693–706. doi: 10.1016/j.molcel.2013.11.009
D’Anello, L., Sansone, P., Storci, G., Mitrugno, V., D’Uva, G., Chieco, P., et al. (2010). Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol. Cancer 9:300. doi: 10.1186/1476-4598-9-300
Darnell, J. E. Jr. (1997). STATs and gene regulation. Science 277, 1630–1635. doi: 10.1126/science.277.5332.1630
David, C. J., and Massague, J. (2018). Contextual determinants of TGFbeta action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419–435. doi: 10.1038/s41580-018-0007-0
Dawood, S., Austin, L., and Cristofanilli, M. (2014). Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) 28, 1101-7, 1107.
Dawson, M. A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27. doi: 10.1016/j.cell.2012.06.013
Dong, C., Wu, Y., Wang, Y., Wang, C., Kang, T., Rychahou, P. G., et al. (2013). Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 32, 1351–1362. doi: 10.1038/onc.2012.169
Dong, C., Wu, Y., Yao, J., Wang, Y., Yu, Y., Rychahou, P. G., et al. (2012). G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J. Clin. Invest. 122, 1469–1486. doi: 10.1172/JCI57349
Drost, J., and Agami, R. (2009). Transformation locked in a loop. Cell 139, 654–656. doi: 10.1016/j.cell.2009.10.035
Dymock, B. W. (2016). The rise of epigenetic drug discovery. Future Med. Chem. 8, 1523–1524. doi: 10.4155/fmc-2016-0158
Dzobo, K., Senthebane, D. A., Rowe, A., Thomford, N. E., Mwapagha, L. M., Al-Awwad, N., et al. (2016). Cancer stem cell hypothesis for therapeutic innovation in clinical oncology? Taking the root out, not chopping the leaf. OMICS 20, 681–691. doi: 10.1089/omi.2016.0152
Easwaran, H., Tsai, H. C., and Baylin, S. B. (2014). Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727. doi: 10.1016/j.molcel.2014.05.015
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., and Flavell, R. A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771. doi: 10.1038/nrc3611
Ernst, M., Thiem, S., Nguyen, P. M., Eissmann, M., and Putoczki, T. L. (2014). Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease. Semin. Immunol. 26, 29–37. doi: 10.1016/j.smim.2013.12.006
Esteller, M. (2007). Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16 Spec No 1, R50–R59. doi: 10.1093/hmg/ddm018
Esteve, P. O., Chin, H. G., and Pradhan, S. (2005). Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc. Natl. Acad. Sci. U.S.A. 102, 1000–1005. doi: 10.1073/pnas.0407729102
Furth, J., Kahn, M. C., and Breedis, C. (1937). The transmission of leukemia of mice with a single cell. Am. J. Cancer 31, 276–282.
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., et al. (2005). 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell Biol. 25, 4727–4741. doi: 10.1128/MCB.25.11.4727-4741.2005
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., et al. (2010). CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120, 485–497. doi: 10.1172/JCI39397
Hao, J., Zhao, S., Zhang, Y., Zhao, Z., Ye, R., Wen, J., et al. (2014). Emerging role of microRNAs in cancer and cancer stem cells. J. Cell Biochem. 115, 605–610. doi: 10.1002/jcb.24702
Hark, A. T., Schoenherr, C. J., Katz, D. J., Ingram, R. S., Levorse, J. M., and Tilghman, S. M. (2000). CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405, 486–489. doi: 10.1038/35013106
Hayden, M. S., and Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344–362. doi: 10.1016/j.cell.2008.01.020
Heim, M. H., Kerr, I. M., Stark, G. R., and Darnell, J. E. Jr. (1995). Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267, 1347–1349. doi: 10.1126/science.7871432
Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grotzinger, J., et al. (1996). Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271, 12999–13007. doi: 10.1074/jbc.271.22.12999
Hmadcha, A., Bedoya, F. J., Sobrino, F., and Pintado, E. (1999). Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. 190, 1595–1604. doi: 10.1084/jem.190.11.1595
Hodge, D. R., Cho, E., Copeland, T. D., Guszczynski, T., Yang, E., Seth, A. K., et al. (2007). IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. Cancer Genomics Proteomics 4, 387–398.
Hodge, D. R., Peng, B., Cherry, J. C., Hurt, E. M., Fox, S. D., Kelley, J. A., et al. (2005). Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 65, 4673–4682. doi: 10.1158/0008-5472.CAN-04-3589
Hoesel, B., and Schmid, J. A. (2013). The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer 12:86. doi: 10.1186/1476-4598-12-86
Hollier, B. G., Evans, K., and Mani, S. A. (2009). The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mam. Gland Biol. Neoplasia 14, 29–43. doi: 10.1007/s10911-009-9110-3
Hu, H. H., Chen, D. Q., Wang, Y. N., Feng, Y. L., Cao, G., Vaziri, N. D., et al. (2018). New insights into TGF-beta/Smad signaling in tissue fibrosis. Chem. Biol. Interact. 292, 76–83. doi: 10.1016/j.cbi.2018.07.008
Hu, T., Yeh, J. E., Pinello, L., Jacob, J., Chakravarthy, S., Yuan, G. C., et al. (2015). Impact of the N-terminal domain of STAT3 in STAT3-dependent transcriptional activity. Mol. Cell Biol. 35, 3284–3300. doi: 10.1128/MCB.00060-15
Hu, Y., Yan, F., Ying, L., and Xu, D. (2017). Emerging roles for epigenetic programming in the control of inflammatory signaling integration in heath and disease. Adv. Exp. Med. Biol. 1024, 63–90. doi: 10.1007/978-981-10-5987-2_3
Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2009). An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693–706. doi: 10.1016/j.cell.2009.10.014
Iliopoulos, D., Hirsch, H. A., Wang, G., and Struhl, K. (2011). Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. U.S.A. 108, 1397–1402. doi: 10.1073/pnas.1018898108
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., and Struhl, K. (2010a). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493–506. doi: 10.1016/j.molcel.2010.07.023
Iliopoulos, D., Lindahl-Allen, M., Polytarchou, C., Hirsch, H. A., Tsichlis, P. N., and Struhl, K. (2010b). Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 39, 761–772. doi: 10.1016/j.molcel.2010.08.013
Jiang, F., Mu, J., Wang, X., Ye, X., Si, L., Ning, S., et al. (2014). The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells. PLoS One 9:e96698. doi: 10.1371/journal.pone.0096698
Jiang, R., Li, Y., Zhang, A., Wang, B., Xu, Y., Xu, W., et al. (2014). The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of let-7c via Ras/NF-kappaB. Toxicol. Lett. 227, 91–98. doi: 10.1016/j.toxlet.2014.03.020
Jones, P. A., and Baylin, S. B. (2007). The epigenomics of cancer. Cell 128, 683–692. doi: 10.1016/j.cell.2007.01.029
Juttermann, R., Li, E., and Jaenisch, R. (1994). Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. U.S.A. 91, 11797–11801. doi: 10.1073/pnas.91.25.11797
Khan, A. Q., Ahmed, E. I., Elareer, N. R., Junejo, K., Steinhoff, M., and Uddin, S. (2019). Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells 8:840. doi: 10.3390/cells8080840
Kim, E., Kim, M., Woo, D. H., Shin, Y., Shin, J., Chang, N., et al. (2013). Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839–852. doi: 10.1016/j.ccr.2013.04.008
Korkaya, H., Kim, G. I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., et al. (2012). Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570–584. doi: 10.1016/j.molcel.2012.06.014
Krishnamurthy, N., and Kurzrock, R. (2018). Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat. Rev. 62, 50–60. doi: 10.1016/j.ctrv.2017.11.002
Krishnamurthy, S., and Nor, J. E. (2012). Head and neck cancer stem cells. J. Dent. Res. 91, 334–340. doi: 10.1177/0022034511423393
Kroon, P., Berry, P. A., Stower, M. J., Rodrigues, G., Mann, V. M., Simms, M., et al. (2013). JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73, 5288–5298. doi: 10.1158/0008-5472.CAN-13-0874
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648. doi: 10.1038/367645a0
Lee, H., Zhang, P., Herrmann, A., Yang, C., Xin, H., Wang, Z., et al. (2012). Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U.S.A. 109, 7765–7769. doi: 10.1073/pnas.1205132109
Li, N., Grivennikov, S. I., and Karin, M. (2011). The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19, 429–431. doi: 10.1016/j.ccr.2011.03.018
Liu, C. C., Lin, J. H., Hsu, T. W., Su, K., Li, A. F., Hsu, H. S., et al. (2015). IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int. J. Cancer 136, 547–559. doi: 10.1002/ijc.29033
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211–215. doi: 10.1038/nm.2284
Liu, K., Liu, Y., Lau, J. L., and Min, J. (2015). Epigenetic targets and drug discovery Part 2: histone demethylation and DNA methylation. Pharmacol. Ther. 151, 121–140. doi: 10.1016/j.pharmthera.2015.04.001
Long, H., Xie, R., Xiang, T., Zhao, Z., Lin, S., Liang, Z., et al. (2012). Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 30, 2309–2319. doi: 10.1002/stem.1194
Lopez-Lazaro, M. (2015). Stem cell division theory of cancer. Cell Cycle 14, 2547–2548. doi: 10.1080/15384101.2015.1062330
Lu, H., Clauser, K. R., Tam, W. L., Frose, J., Ye, X., Eaton, E. N., et al. (2014). A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 16, 1105–1117. doi: 10.1038/ncb3041
Ma, R., Liu, Q., Zheng, S., Liu, T., Tan, D., and Lu, X. (2019). PKM2-regulated STAT3 promotes esophageal squamous cell carcinoma progression via TGF-beta1-induced EMT. J. Cell Biochem. 120, 11539–11550. doi: 10.1002/jcb.28434
Ma, T. T., and Meng, X. M. (2019). TGF-beta/smad and renal fibrosis. Adv. Exp. Med. Biol. 1165, 347–364. doi: 10.1007/978-981-13-8871-2_16
Massague, J. (2012). TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630. doi: 10.1038/nrm3434
Massague, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. Genes Dev. 19, 2783–2810. doi: 10.1101/gad.1350705
Matsui, W. H. (2016). Cancer stem cell signaling pathways. Medicine (Baltimore) 95, S8–S19. doi: 10.1097/MD.0000000000004765
May, M. J., and Ghosh, S. (1997). Rel/NF-kappa B and I kappa B proteins: an overview. Semin. Cancer Biol. 8, 63–73. doi: 10.1006/scbi.1997.0057
McGrath, J., and Trojer, P. (2015). Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1–22. doi: 10.1016/j.pharmthera.2015.01.002
Meacham, C. E., and Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337. doi: 10.1038/nature12624
Morita, R., Hirohashi, Y., Suzuki, H., Takahashi, A., Tamura, Y., Kanaseki, T., et al. (2013). DNA methyltransferase 1 is essential for initiation of the colon cancers. Exp. Mol. Pathol. 94, 322–329. doi: 10.1016/j.yexmp.2012.10.004
Moustakas, A., Souchelnytskyi, S., and Heldin, C. H. (2001). Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114, 4359–4369. doi: 10.1242/jcs.114.24.4359
Najafi, M., Farhood, B., and Mortezaee, K. (2019). Cancer stem cells (CSCs) in cancer progression and therapy. J. Cell Physiol. 234, 8381–8395. doi: 10.1002/jcp.27740
Nieto, M. A. (2013). Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342:1234850. doi: 10.1126/science.1234850
Nieto, M. A., Huang, R. Y., Jackson, R. A., and Thiery, J. P. (2016). Emt: 2016. Cell 166, 21–45. doi: 10.1016/j.cell.2016.06.028
Novack, D. V. (2011). Role of NF-kappaB in the skeleton. Cell Res. 21, 169–182. doi: 10.1038/cr.2010.159
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., et al. (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39, 237–242. doi: 10.1038/ng1972
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., et al. (2007). Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109–3115. doi: 10.1200/JCO.2006.10.2434
Pan, Y., Ma, S., Cao, K., Zhou, S., Zhao, A., Li, M., et al. (2018). Therapeutic approaches targeting cancer stem cells. J. Cancer Res. Ther. 14, 1469–1475. doi: 10.4103/jcrt.JCRT_976_17
Pang, X., Tang, Y. L., and Liang, X. H. (2018). Transforming growth factor-beta signaling in head and neck squamous cell carcinoma: insights into cellular responses. Oncol. Lett. 16, 4799–4806. doi: 10.3892/ol.2018.9319
Park, S. Y., Lee, C. J., Choi, J. H., Kim, J. H., Kim, J. W., Kim, J. Y., et al. (2019). The JAK2/STAT3/CCND2 axis promotes colorectal cancer stem cell persistence and radioresistance. J. Exp. Clin. Cancer Res. 38:399. doi: 10.1186/s13046-019-1405-7
Perkins, N. D., and Gilmore, T. D. (2006). Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 13, 759–772. doi: 10.1038/sj.cdd.4401838
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., et al. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27, 5410–5417. doi: 10.1200/JCO.2008.21.6150
Plaks, V., Kong, N., and Werb, Z. (2015). The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238. doi: 10.1016/j.stem.2015.02.015
Reik, W. (2007). Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447, 425–432. doi: 10.1038/nature05918
Ren, D., Yang, Q., Dai, Y., Guo, W., Du, H., Song, L., et al. (2017b). Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappaB signaling pathway. Mol. Cancer 16:117. doi: 10.1186/s12943-017-0688-6
Ren, D., Lin, B., Zhang, X., Peng, Y., Ye, Z., Ma, Y., et al. (2017a). Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget 8, 49807–49823. doi: 10.18632/oncotarget.17971
Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105–111. doi: 10.1038/35102167
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., et al. (2012). EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361. doi: 10.1016/j.cell.2011.11.025
Rokavec, M., Oner, M. G., and Hermeking, H. (2016). lnflammation-induced epigenetic switches in cancer. Cell Mol. Life Sci. 73, 23–39. doi: 10.1007/s00018-015-2045-5
Rokavec, M., Oner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., et al. (2014). IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124, 1853–1867. doi: 10.1172/JCI73531
Rokavec, M., Wu, W., and Luo, J. L. (2012). IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol. Cell 45, 777–789. doi: 10.1016/j.molcel.2012.01.015
Sakamoto, K., Wehde, B. L., Yoo, K. H., Kim, T., Rajbhandari, N., Shin, H. Y., et al. (2016). Janus kinase 1 is essential for inflammatory cytokine signaling and mammary gland remodeling. Mol. Cell. Biol. 36, 1673–1690. doi: 10.1128/MCB.00999-15
Scheel, C., and Weinberg, R. A. (2012). Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396–403. doi: 10.1016/j.semcancer.2012.04.001
Schenk, T., Chen, W. C., Gollner, S., Howell, L., Jin, L., Hebestreit, K., et al. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605–611. doi: 10.1038/nm.2661
Sferra, R., Pompili, S., Festuccia, C., Marampon, F., Gravina, G. L., Ventura, L., et al. (2017). The possible prognostic role of histone deacetylase and transforming growth factor beta/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. Eur. J. Histochem. 61:2732. doi: 10.4081/ejh.2017.2732
Sharma, S., Kelly, T. K., and Jones, P. A. (2010). Epigenetics in cancer. Carcinogenesis 31, 27–36. doi: 10.1093/carcin/bgp220
Shyh-Chang, N., and Daley, G. Q. (2013). Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 12, 395–406. doi: 10.1016/j.stem.2013.03.005
Singh, V., Singh, A. P., Sharma, I., Singh, L. C., Sharma, J., Borthakar, B. B., et al. (2019). Epigenetic deregulations of Wnt/beta-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: outcome of DNA methylation. J. Cancer Res. Ther. 15, 192–203.
Stresemann, C., and Lyko, F. (2008). Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8–13. doi: 10.1002/ijc.23607
Sun, L., Mathews, L. A., Cabarcas, S. M., Zhang, X., Yang, A., Zhang, Y., et al. (2013). Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells 31, 1454–1466. doi: 10.1002/stem.1394
Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71–85. doi: 10.1038/cr.2010.177
Tang, Y. N., Ding, W. Q., Guo, X. J., Yuan, X. W., Wang, D. M., and Song, J. G. (2015). Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat. Commun. 6:8230. doi: 10.1038/ncomms9230
Travaglini, L., Vian, L., Billi, M., Grignani, F., and Nervi, C. (2009). Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int. J. Biochem. Cell Biol. 41, 225–234.
Vahidian, F., Mohammadi, H., Ali-Hasanzadeh, M., Derakhshani, A., Mostaan, M., Hemmatzadeh, M., et al. (2019). MicroRNAs and breast cancer stem cells: potential role in breast cancer therapy. J. Cell Physiol. 234, 3294–3306.
Wade, P. A., Gegonne, A., Jones, P. L., Ballestar, E., Aubry, F., and Wolffe, A. P. (1999). Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23, 62–66.
Walker, S. R., Xiang, M., and Frank, D. A. (2014). STAT3 activity and function in cancer: modulation by STAT5 and miR-146b. Cancers (Basel) 6, 958–968.
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487–1495.
Xiao, G., Harhaj, E. W., and Sun, S. C. (2001). NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7, 401–409.
Xu, F., Liu, C., Zhou, D., and Zhang, L. (2016). TGF-beta/SMAD pathway and its regulation in hepatic fibrosis. J. Histochem. Cytochem. 64, 157–167.
Yang, Y., Ding, L., Hu, Q., Xia, J., Sun, J., Wang, X., et al. (2017). MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Mol. Cancer 16:141.
Ye, J., Lei, J., Fang, Q., Shen, Y., Xia, W., Hu, X., et al. (2019). miR-4666-3p and miR-329 Synergistically suppress the stemness of colorectal cancer cells via targeting TGF-beta/Smad pathway. Front. Oncol. 9:1251. doi: 10.3389/fonc.2019.01251
You, H., Ding, W., and Rountree, C. B. (2010). Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51, 1635–1644.
Yu, D., Shin, H. S., Lee, Y. S., and Lee, Y. C. (2014). miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells. Lab. Invest. 94, 1370–1381.
Yu, Z., Pestell, T. G., Lisanti, M. P., and Pestell, R. G. (2012). Cancer stem cells. Int. J. Biochem. Cell Biol. 44, 2144–2151.
Yuan, Z. L., Guan, Y. J., Chatterjee, D., and Chin, Y. E. (2005). Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269–273.
Zahnow, C. A., and Baylin, S. B. (2010). Epigenetic networks and miRNAs in stem cells and cancer. Mol. Cell 39, 661–663.
Zhang, Q., Lenardo, M. J., and Baltimore, D. (2017). 30 Years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell 168, 37–57.
Zhang, T., Kee, W. H., Seow, K. T., Fung, W., and Cao, X. (2000). The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol. Cell. Biol. 20, 7132–7139.
Zhang, X., Wrzeszczynska, M. H., Horvath, C. M., and Darnell, J. E. Jr. (1999). Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol. Cell. Biol. 19, 7138–7146.
Keywords: cancer stem cells, epigenetics, inflammation, inflammatory factors, signaling pathway
Citation: Liu Z, Ren Y, Meng L, Li L, Beatson R, Deng J, Zhang T, Liu J and Han X (2021) Epigenetic Signaling of Cancer Stem Cells During Inflammation. Front. Cell Dev. Biol. 9:772211. doi: 10.3389/fcell.2021.772211
Received: 07 September 2021; Accepted: 21 September 2021;
Published: 15 October 2021.
Edited by:
Chong Li, Institute of Biophysics, Chinese Academy of Sciences (CAS), ChinaReviewed by:
Yijing Su, University of Pennsylvania, United StatesLu Liu, Hannover Medical School, Germany
Copyright © 2021 Liu, Ren, Meng, Li, Beatson, Deng, Zhang, Liu and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xinwei Han, ZmNjaGFueHdAenp1LmVkdS5jbg==; Junqi Liu, ZmNjaXVqcUB6enUuZWR1LmNu; Tengfei Zhang, YmlvamFjb2JAZ21haWwuY29t
†These authors have contributed equally to this work and share first authorship